February 2025's Top Stocks That May Be Trading Below Estimated Value

As global markets experience a mix of record-high stock indexes and inflation-driven economic uncertainties, investors are keenly observing the shifting landscape for potential opportunities. In this context, identifying stocks that may be trading below their estimated value becomes particularly appealing, as these could offer significant upside potential amidst the current market conditions.

Top 10 Undervalued Stocks Based On Cash Flows

Name	Current Price	Fair Value (Est)	Discount (Est)
Provident Financial Services (NYSE:PFS)	US$18.66	US$36.99	49.6%
Hancom (KOSDAQ:A030520)	₩24650.00	₩49094.79	49.8%
Nuvoton Technology (TWSE:4919)	NT$96.10	NT$191.31	49.8%
Smurfit Westrock (NYSE:SW)	US$55.30	US$109.74	49.6%
IDP Education (ASX:IEL)	A$12.12	A$24.11	49.7%
Solum (KOSE:A248070)	₩17610.00	₩34899.00	49.5%
Com2uS (KOSDAQ:A078340)	₩48200.00	₩96034.26	49.8%
Saipem (BIT:SPM)	€2.341	€4.67	49.8%
Likewise Group (AIM:LIKE)	£0.185	£0.37	49.8%
Constellium (NYSE:CSTM)	US$9.24	US$18.27	49.4%

Click here to see the full list of 924 stocks from our Undervalued Stocks Based On Cash Flows screener.

Let's take a closer look at a couple of our picks from the screened companies.

Saipem (BIT:SPM)

Overview: Saipem SpA is a global provider of energy and infrastructure solutions with a market cap of €4.58 billion.

Operations: The company generates revenue from its Energy Carriers segment (€5.87 billion), Offshore Drilling (€1.40 billion), and Asset Based Services (€10.86 billion).

Estimated Discount To Fair Value: 49.8%

Saipem is trading at €2.34, significantly below its estimated fair value of €4.67, indicating it is highly undervalued based on cash flows. The company recently secured a substantial US$1 billion contract for the Tangguh UCC Project in Indonesia, enhancing its position in natural gas and CO2 capture sectors. Saipem's earnings are forecast to grow at 24.21% annually, outpacing the Italian market's growth rate of 7.6%.

• Our comprehensive growth report raises the possibility that Saipem is poised for substantial financial growth.
• Take a closer look at Saipem's balance sheet health here in our report.

Exosens (ENXTPA:EXENS)

Overview: Exosens develops, manufactures, and sells electro-optical technologies focused on amplification, detection, and imaging across multiple regions including Europe, North America, Asia, Oceania, Africa and has a market cap of €1.19 billion.

Operations: Exosens generates revenue through the development, manufacturing, and sale of electro-optical technologies in amplification, detection, and imaging across regions such as Europe, North America, Asia, Oceania, and Africa.

Estimated Discount To Fair Value: 44.5%

Exosens is trading at €23.5, significantly below its estimated fair value of €42.36, highlighting its undervaluation based on cash flows. The company recently launched advanced photon detection products, Crickettm Pro and PhotonPixtm, enhancing capabilities in scientific imaging and detection markets. With forecasted earnings growth of 36.5% annually and revenue growth outpacing the French market, Exosens shows strong potential despite recent profit margin declines and share price volatility.

• The analysis detailed in our Exosens growth report hints at robust future financial performance.
• Click here and access our complete balance sheet health report to understand the dynamics of Exosens.

Orion Oyj (HLSE:ORNBV)

Overview: Orion Oyj is a company that develops, manufactures, and markets human and veterinary pharmaceuticals as well as active pharmaceutical ingredients (APIs) across Finland, Scandinavia, the rest of Europe, North America, and internationally with a market cap of €7.38 billion.

Operations: The company's revenue segment is primarily comprised of Pharmaceuticals, generating €1.43 billion.

Estimated Discount To Fair Value: 29.9%

Orion Oyj is trading at €52.7, well below its estimated fair value of €75.19, indicating a significant undervaluation based on cash flows. The company forecasts earnings growth of 12.8% annually, outpacing the Finnish market's average growth rate. Recent strategic collaborations in antibody discovery and a raised earnings guidance for 2024 underscore Orion's commitment to innovation and expansion, although its dividend coverage by free cash flows remains inadequate.

• According our earnings growth report, there's an indication that Orion Oyj might be ready to expand.
• Click here to discover the nuances of Orion Oyj with our detailed financial health report.

Summing It All Up

• Embark on your investment journey to our 924 Undervalued Stocks Based On Cash Flows selection here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com